| Cefiderocol for the treatment of infections due to metallo-B-lactamase–Producing pathogens in the CREDIBLE-CR and APEKS-NP phase 3 randomized studies JF Timsit, M Paul, RK Shields, R Echols, T Baba, Y Yamano, ... Clinical Infectious Diseases 75 (6), 1081-1084, 2022 | 49 | 2022 |
| Improving traditional registrational trial end points: development and application of a desirability of outcome ranking end point for complicated urinary tract infection … J Howard-Anderson, T Hamasaki, W Dai, D Collyar, D Rubin, S Nambiar, ... Clinical Infectious Diseases 76 (3), e1157-e1165, 2023 | 17 | 2023 |
| Peripheral endothelial function can be improved by daily consumption of water containing over 7 ppm of dissolved hydrogen: A randomized controlled trial T Ishibashi, K Kawamoto, K Matsuno, G Ishihara, T Baba, N Komori PLoS One 15 (5), e0233484, 2020 | 16 | 2020 |
| Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double‐blind, randomized, placebo‐controlled, phase 2 clinical trial M Kato, K Nakagome, T Baba, T Sonoyama, D Okutsu, H Yamanaka, ... Psychiatry and Clinical Neurosciences 77 (9), 497-509, 2023 | 14 | 2023 |
| A criterion for semiparametric causal inference T Baba, T Kanemori, Y Ninomiya Biometrika 104 (4), 845-861, 2017 | 11 | 2017 |
| Outcomes with cefiderocol treatment in patients with bacteraemia enrolled into prospective phase 2 and phase 3 randomised clinical studies DL Paterson, M Kinoshita, T Baba, R Echols, S Portsmouth Infectious Diseases and Therapy 11 (2), 853-870, 2022 | 10 | 2022 |
| Evidence for efficacy of cefiderocol against OXA-48-containing isolates from the APEKS-NP and CREDIBLE-CR trials C Longshaw, E Roger, A Santerre Henriksen, T Baba, S Nguyen, ... Antimicrobial Agents and Chemotherapy 66 (10), e01100-22, 2022 | 7 | 2022 |
| Heteroresistance to cefiderocol in carbapenem-resistant Acinetobacter baumannii in the CREDIBLE-CR study was not linked to clinical outcomes: A post hoc analysis C Longshaw, A Santerre Henriksen, D Dressel, M Malysa, C Silvestri, ... Microbiology Spectrum 11 (6), e02371-23, 2023 | 5 | 2023 |
| Simplified virtual reality system can be used to evaluate the temporal discrimination ability in softball batting as in the real environment D Nasu, T Baba, T Imamura, M Yamaguchi, Y Kitanishi, M Kashino Frontiers in Sports and Active Living 4, 843896, 2022 | 3 | 2022 |
| Reconstructing the household transmission of influenza in the suburbs of Tokyo based on clinical cases MM Saito, N Hirotsu, H Hamada, M Takei, K Honda, T Baba, T Hasegawa, ... Theoretical Biology and Medical Modelling 18, 1-10, 2021 | 3 | 2021 |
| Relationship between baseline clinical characteristics and efficacy of lusutrombopag in thrombocytopenic patients with chronic liver disease: post hoc analysis of … K Tanaka, T Baba, M Yoshida, M Iguchi, T Sonoyama, T Fukuhara, ... Current Medical Research and Opinion 38 (2), 303-310, 2022 | 1 | 2022 |
| Comparative Effectiveness of Baloxavir Marboxil and Oseltamivir Treatment in Reducing Household Transmission of Influenza: A Post Hoc Analysis of the BLOCKSTONE Trial H Ikematsu, T Baba, MM Saito, M Kinoshita, S Miyazawa, A Hata, ... Influenza and Other Respiratory Viruses 18 (5), e13302, 2024 | | 2024 |
| Virtual reality perceptual training can improve the temporal discrimination ability of swinging during softball batting D Nasu, T Baba, T Imamura, M Yamaguchi, Y Kitanishi, M Kashino Frontiers in Sports and Active Living 6, 1332149, 2024 | | 2024 |
| L'hétérorésistance au céfidérocol chez Acinetobacter baumannii n'est pas la cause de la différence de mortalité observée dans l'étude CREDIBLE-CR C Longshaw, AS Henriksen, D Dressel, M Malysa, C Silvestri, ... Médecine et Maladies Infectieuses Formation 2 (2), S73, 2023 | | 2023 |
| Doubly Robust Criterion for Causal Inference T Baba, Y Ninomiya arXiv preprint arXiv:2110.14525, 2021 | | 2021 |
| Comparison of Hospitalization and Death Frequencies in Influenza Outpatients Treated with Baloxavir marboxil or Neuraminidase Inhibitors: an Observational Database Study H MIYAUCHI, T KOMEDA, M FUJIWARA, B Takamichi, S MIYAZAWA, ... Japanese Journal of Pharmacoepidemiology, 15-26, 2021 | | 2021 |
